In vitro susceptibility to ceftazidime/avibactam and comparators in clinical isolates of enterobacterales from five Latin American Countries
Autor: | Tobias Manuel Appel, Elsa De La Cadena, Ana Cristina Gales, Marcela Alejandra Radice, Maria F. Mojica, Maria V. Villegas, Paulo F Castañeda-Mendez, Diego A Jaime-Villalón, Jose M. Munita, Christian Pallares |
---|---|
Přispěvatelé: | Mojica, María Fernanda [0000-0002-1380-9824], de la Cadena, Elsa [0000-0003-0361-7893], Pallares, Christian José [0000-0002-6093-7845], Villegas, María Virginia [0000-0003-1898-9067] |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Carbapenem Antibiotic susceptibility Cephalosporin Ceftazidime Ciencias de la Salud Tigecycline Antimicrobial activity Biochemistry Ceftazidime/Avibactam chemistry.chemical_compound 0302 clinical medicine Enterobacterales colombia Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Brief Report chile Enterobacter aerogenes Otras Ciencias de la Salud Klebsiella pneumoniae Infectious Diseases brazil purl.org/becyt/ford/3 [https] Ertapenem geographic locations medicine.drug Microbiology (medical) CIENCIAS MÉDICAS Y DE LA SALUD medicine.drug_class Avibactam 030106 microbiology Argentina Farmacorresistencia microbiana Fosfomycin Biology Colombia Microbiology 03 medical and health sciences purl.org/becyt/ford/3.3 [https] parasitic diseases medicine argentina mexico antimicrobial activity lcsh:RM1-950 Ceftazidime/avibactam lcsh:Therapeutics. Pharmacology chemistry |
Zdroj: | Antibiotics, Vol 9, Iss 2, p 62 (2020) Repositorio U. El Bosque Universidad El Bosque instacron:Universidad El Bosque Antibiotics CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET |
Popis: | Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America Fil: Appel, Tobias Manuel. Universidad El Bosque; Colombia Fil: Mojica, Maria Fernanda. Universidad El Bosque; Colombia Fil: De La Cadena, Elsa. Universidad El Bosque; Colombia Fil: Pallares, Cristian. Universidad El Bosque; Colombia Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Castañeda Méndez, Paulo. Hospital Médica Sur; México Fil: Jaime-Villalón, Diego. Hospital San Angel; México Fil: Gales, Ana. Universidade de Sao Paulo; Brasil Fil: Munita, Jose. No especifíca; Fil: Villegas, Maria. Universidad El Bosque; Colombia |
Databáze: | OpenAIRE |
Externí odkaz: |